Princeton Capital Management LLC trimmed its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 4.9% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 48,023 shares of the company’s stock after selling 2,499 shares during the period. Novo Nordisk A/S accounts for approximately 0.9% of Princeton Capital Management LLC’s holdings, making the stock its 29th largest holding. Princeton Capital Management LLC’s holdings in Novo Nordisk A/S were worth $2,264,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also made changes to their positions in NVO. Renaissance Technologies LLC raised its stake in shares of Novo Nordisk A/S by 12.0% during the 2nd quarter. Renaissance Technologies LLC now owns 19,142,300 shares of the company’s stock worth $882,843,000 after buying an additional 2,051,000 shares during the period. Envestnet Asset Management Inc. increased its position in shares of Novo Nordisk A/S by 943.0% during the second quarter. Envestnet Asset Management Inc. now owns 625,349 shares of the company’s stock worth $28,841,000 after purchasing an additional 565,395 shares in the last quarter. First Trust Advisors LP increased its position in shares of Novo Nordisk A/S by 4,736.6% during the second quarter. First Trust Advisors LP now owns 466,631 shares of the company’s stock worth $21,521,000 after purchasing an additional 456,983 shares in the last quarter. Caisse DE Depot ET Placement DU Quebec purchased a new stake in shares of Novo Nordisk A/S during the second quarter worth approximately $10,515,000. Finally, Fisher Asset Management LLC increased its position in shares of Novo Nordisk A/S by 1.7% during the third quarter. Fisher Asset Management LLC now owns 13,797,404 shares of the company’s stock worth $650,410,000 after purchasing an additional 227,733 shares in the last quarter. 6.72% of the stock is owned by institutional investors and hedge funds.

Shares of NVO traded down $1.01 during trading hours on Thursday, hitting $43.45. 21,349 shares of the stock were exchanged, compared to its average volume of 1,528,544. The stock has a market capitalization of $108.83 billion, a price-to-earnings ratio of 18.60, a PEG ratio of 2.36 and a beta of 0.76. Novo Nordisk A/S has a 12-month low of $41.23 and a 12-month high of $58.37.

Several analysts recently commented on NVO shares. Zacks Investment Research cut Novo Nordisk A/S from a “buy” rating to a “sell” rating in a research report on Wednesday, October 10th. HSBC reiterated a “sell” rating on shares of Novo Nordisk A/S in a research report on Tuesday, November 6th. ValuEngine upgraded Novo Nordisk A/S from a “sell” rating to a “hold” rating in a research report on Saturday, October 27th. Deutsche Bank reiterated a “buy” rating on shares of Novo Nordisk A/S in a research report on Thursday, October 4th. Finally, Bank of America cut Novo Nordisk A/S from a “buy” rating to a “neutral” rating in a research report on Monday, October 8th. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating and four have given a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $64.00.

TRADEMARK VIOLATION NOTICE: This story was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this story on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this story can be accessed at https://www.thecerbatgem.com/2018/11/15/novo-nordisk-a-s-nvo-shares-sold-by-princeton-capital-management-llc.html.

Novo Nordisk A/S Profile

Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides insulins, GLP-1 and related delivery systems, and oral anti-diabetic drugs and obesity.

Read More: Why do companies engage in swaps?

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO).

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.